Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.
Valuation & Earnings
This table compares Senti Biosciences and Bicara Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $2.56 million | 16.45 | -$52.79 million | ($8.95) | -0.18 |
| Bicara Therapeutics | N/A | N/A | -$68.00 million | ($2.24) | -6.60 |
Analyst Ratings
This is a summary of recent recommendations for Senti Biosciences and Bicara Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Bicara Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Senti Biosciences presently has a consensus target price of $9.67, suggesting a potential upside of 500.41%. Bicara Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 100.73%. Given Senti Biosciences’ higher probable upside, equities analysts plainly believe Senti Biosciences is more favorable than Bicara Therapeutics.
Profitability
This table compares Senti Biosciences and Bicara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -161.91% | -57.29% |
| Bicara Therapeutics | N/A | -27.17% | -26.05% |
Insider and Institutional Ownership
25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Senti Biosciences has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Bicara Therapeutics has a beta of -0.76, meaning that its share price is 176% less volatile than the S&P 500.
Summary
Senti Biosciences beats Bicara Therapeutics on 6 of the 11 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Bicara Therapeutics
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
